People · Operator
Named in public records as an officer, director or promoter · active 2009–2019 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ardelyx, Inc. | — | Pharmaceuticals | Series D+ | $210.4M | $3.9B | 2010 |
| Sagimet Biosciences Inc. | — | Biotechnology | Series C | $166.6M | $2.4B | 2009 |
| Adaptimmune Ltd | — | Biotechnology | Series D+ | $103.8M | $4.3B | 2014 |
| Mersana Therapeutics Inc | — | Biotechnology | Series B | $93.7M | $1.3B | 2013 |
| Omthera Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $92.7M | $598.5M | 2011 |
| Prosensa Holding N.V. | — | Biotechnology | Series C | $50.5M | $2.1B | 2014 |
| XTuit Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $39.5M | $748.7M | 2014 |
| Cydan, LLC | — | Pharmaceuticals | Series A | $10.6M | $204.5M | 2013 |
| Edimer Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $9.8M | $303.4M | 2013 |
David Mott at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Mott on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Annalisa Jenkins | 2 | 8 |
| Gordon Ringold | 2 | 7 |
| Sara Nayeem | 2 | 4 |
| Richard Rodgers | 2 | 4 |
| Robert Langer | 1 | 36 |
| Ali Behbahani | 1 | 17 |
| Peter Thompson | 1 | 16 |
| Beth Seidenberg | 1 | 15 |
| Alan Crane | 1 | 9 |
| David Collier | 1 | 8 |
| Robert Garland | 1 | 7 |
| Thomas Beck | 1 | 7 |
| Elaine Jones | 1 | 6 |
| Mitchell Bloom | 1 | 6 |
| Michael Wyzga | 1 | 5 |
| Cary Pfeffer | 1 | 4 |
| James Young | 1 | 4 |
| C. Boyd Clarke | 1 | 4 |
| Christoph M. Adams | 1 | 4 |
| Michael Davidson | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.